Succession Plan at Biocon: Kiran Mazumdar-Shaw Backs Niece Claire Mazumdar for Top Role

In an industry where leadership transitions are often abrupt or opaque, Kiran Mazumdar-Shaw has opted for a measured and transparent approach, signalling continuity while preparing for change at Biocon.

The Biocon founder and chairperson has formally outlined a succession plan, naming her niece Claire Mazumdar as her chosen successor.

Having built the biotechnology company over more than four decades and without a direct heir, Mazumdar-Shaw said she believes Claire is well-suited to guide the company’s next phase, which is expected to be shaped by advancements in biotechnology and artificial intelligence.

Mazumdar-Shaw, 73, who transformed Biocon into a leading biopharmaceutical enterprise, emphasised that her priority is to ensure the company remains in capable hands.

“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” she told Fortune India.

The transition, however, will not be immediate. Mazumdar-Shaw clarified that she will continue in her current role while Claire progressively takes on greater responsibilities within the organisation.

What experience does Claire Mazumdar bring from leading Bicara Therapeutics?

Claire Mazumdar, 37, currently serves as founder and chief executive officer of Bicara Therapeutics.

She led the company from its inception to its NASDAQ listing in 2024, with its valuation crossing $800 million at debut and rising to over $1.6 billion in market capitalisation.

Bicara’s lead programme focuses on a bifunctional antibody targeting head and neck cancers and remains under clinical development, with ongoing global trials.

Mazumdar-Shaw highlighted this as evidence of Claire’s ability to scale and lead in a competitive global environment.

Claire’s academic credentials include degrees from Massachusetts Institute of Technology and Stanford University, along with a PhD in cancer biology. She has also worked with Third Rock Ventures and Rheos Medicines.

She currently serves on the boards of Relay Therapeutics and Noora Health, the latter focusing on improving patient outcomes by training family caregivers.

Mazumdar-Shaw also pointed to a broader support network within the family that could contribute to Biocon’s future direction, including Claire’s brother Eric Mazumdar, a professor at California Institute of Technology, and her husband Thomas Roberts, who is associated with Massachusetts General Hospital.

Claire is married to Roberts, an oncologist based in the United States.

Alongside succession planning, Biocon has undertaken a broader restructuring, combining its generics and biologics divisions, working to reduce its debt burden, and streamlining its overall structure.